PDL BioPharma Inc

PDL BioPharma — Proxy Contest (January 2020)

19 slides from PDL BioPharma's proxy contest presentation, Jan 15, 2020

  1. Slide 1: Maximizing Shareholder Value

    PDL Maximizing Shareholder Value January 2020 PDL BioPharma, Inc. Nasdaq: PDLI PDL.com

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements including PDL's expectations with respect to its future royalty revenues, expenses, net income and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actual

  3. Slide 3: Important Additional Information and Where to Find It

    Important Additional Information and Where to Find It ‘The Company plans to fle a proxy statement (the "2020 Proxy Statement’) with the U.S. Secunties and Exchange Commission (the "SEC’) in connection with the solicitation of proxies for the Company's 2020 annual meeting of stockholders (the “2020 A

  4. Slide 4: Presentation Overview

    Presentation Overview I. Introduction to PDL BioPharma Il. Execution against strategic plan in 2019 Ill. Undertaking the strategic review IV. Transitioning from healthcare growth strategy to a monetization process V. Overview of governance, Board of Directors and CSR

  5. Slide 5: About PDL BioPharma

    About PDL BioPharma E¥OFEM LENSAR NOD y PHARMA ical-stage women’s health Next-generation femtosecond Global specialty ‘company laser technology for refractive pharmaceutical company cataract surgery PDL has ~30% equity stake PDL owns ~94% Wholly-owned by PDL Passive gicelx ASSERTIOS Royalty and Debt

  6. Slide 6: Strong Execution in 2019

    Strong Execution in 2019 ° Significant year-over-year sales growth and progress with next generation at LENSAR + Investments paying off as 2019 sales were tracking ahead of full year guidance at Q3'19 + Investing in the development of GEN2, first compact, integrated workstation combining state-of-th

  7. Slide 7: Transitioning from Growth Strategy to Monetization Process

    Transitioning from Growth Strategy to Monetization Process ° ° Despite strong execution, PDL’s shares continued to trade at a discount to book value Management recommended to the Board of Directors in summer of 2019 that PDL undertake a strategic review Board and management began the review in Septe

  8. Slide 8: Unlocking Shareholder Value

    Unlocking Shareholder Value o Management is leading the process, which is being overseen by a newly formed committee of the Board of Directors o Company is in process of retaining financial advisors to assist with asset sales o PDLis exploring a variety of potential transactions, including a sale, d

  9. Slide 9: Excellent Progress in a Short Time

    Excellent Progress in a Short Time o PDL has already repurchased shares and convertible notes and made changes to its Board during the one-month period following announcement of the monetization plan o Board approved an aggregate repurchase of $275M of shares and convertible notes + Retired $119.3M

  10. Slide 10: Corporate Governance Overview

    10 Corporate Governance Overview o Independent Chairperson o Highly diverse Board in terms of skills, experience and gender o Majority voting on election of directors o Significant recent Board refreshment, with 50% of the Board having been replaced since June 2018 o Majority vote required to amend

  11. Slide 11: Highly-Experienced and Diverse Board of Directors

    "1 Highly-Experienced and Diverse Board of Directors Elizabeth O'Farrell” David Gryska Natasha A. Hernday* John McLaughlin Monnet” Paul Sandman** Shlomo Yanai* Diversity Contribute tothe board perspectives through diversity in gender, ethnicty and race v v Financial Acumen & Expertise Experience or

  12. Slide 12: Compensation and Governance Highlights

    Compensation and Governance Highlights What We Do CEO's annual cash bonus is 100% attributable to the achievement of corporate goals set by the Compensation Committee and ratified by the Board and is fully at risk of non-payment in the event of unsatisfactory performance We restructured our long-ter

  13. Slide 13: Corporate Social Responsibility

    Corporate Social Responsibility o PDL's mission has been to improve the lives of patients by aiding in the successful development of innovative therapeutics and healthcare technologies o Previously pioneered the humanization of monoclonal antibodies, enabling the discovery of a new generation of tar

  14. Slide 14: Unlocking Shareholder Value

    Unlocking Shareholder Value Monetizing portfolio of commercial-stage assets and legacy portfolio of royalty and debt investments Focused on conducting process in a disciplined and cost-effective manner and on a timetable that will maximize value for our shareholders Significant progress has already

  15. Slide 15: Appendix

    PDL Appendix

  16. Slide 16: Leveraging NOLs at LENSAR

    Leveraging NOLs at LENSAR LENSAR The LENSAR® Laser System Only femtosecond cataract laser built specifically for refractive cataract surgery Designed from the ground up: every aspect of the laser has been purposefully designed to meet the needs of cataract surgeons LENSAR continuously advances the t

  17. Slide 17: Well-Positioned for Value Creation at Evofem

    Well-Positioned for Value E¥ Creation at Evofem OFEM BIOSCIENCE S* Clinical stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women’s sexual and reproductive health Multipurpose Vaginal pH Regulator™ (MVP-R) gel technology + Non

  18. Slide 18: Driving Profitability at Noden Pharma

    48 Driving Profitability at Noden xoven Sh rnarma Tekturna® Only approved direct renin inhibitor for the management of hypertension + Targets a chemical in the body called renin, which starts a process in the body that causes your blood vessels to narrow and raises your blood pressure May be an alte

  19. Slide 19: GAAP to Non-GAAP Net (Loss) Income Reconciliation

    GAAP to Non-GAAP Net (Loss) Income Reconciliation GAAP to Non-GAAP Net (Loss) Income Reconciliation (in thousands) GAAP net loss attributed to PDL’s shareholders, as reported Adjustments: Mark-to-market adjustment to fair value - royaltyassets Mark-to-market adjustments to equity affiliate - common

PDL BioPharma — Proxy Contest (January 2020) on 6ix